Development and potential clinical uses of human prolactin receptor antagonists

被引:165
作者
Goffin, V
Bernichtein, S
Touraine, P
Kelly, PA
机构
[1] Fac Med Necker Enfants Malad, INSERM, U584, F-75730 Paris, France
[2] Univ Paris 05, F-75730 Paris, France
[3] Hop Necker Enfants Malad, Serv Endocrinol & Med Reprod, F-75743 Paris, France
关键词
D O I
10.1210/er.2004-0016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is a large body of literature showing that prolactin (PRL) exerts growth-promoting activities in breast cancer, and possibly in prostate cancer and prostate hyperplasia. In addition, increasing evidence argues for the involvement of locally produced ( autocrine) PRL, perhaps even more than pituitary-secreted ( endocrine) PRL, in tumor growth. Because dopamine analogs are unable to inhibit PRL production in extrapituitary sites, alternative strategies need investigation. To that end, several PRL receptor antagonists have been developed by introducing various mutations into its natural ligands. For all but one of these analogs, the mechanism of action involves a competition with endogenous PRL for receptor binding. Such compounds are thus candidates to counteract the undesired actions of PRL, not only in tumors, but also in dopamine-resistant prolactinomas. In this review, we describe the different versions of antagonists that have been developed, with emphasis on the controversies regarding their characterization, and the limits for their potential development as a drug. The most recently developed antagonist, Delta 1 - 9-G129R-hPRL, is the only one that is totally devoid of residual agonistic activity, meaning it acts as pure antagonist. We discuss to what extent this new molecule could be considered as a lead compound for inhibiting the actions of human PRL in the above-mentioned diseases. We also speculate on the multiple questions that could be addressed with respect to the therapeutic use of PRL receptor antagonists in patients.
引用
收藏
页码:400 / 422
页数:23
相关论文
共 156 条
  • [71] Prolactin receptor messenger ribonucleic acid in normal and neoplastic human pituitary tissues
    Jin, L
    Qian, X
    Kulig, E
    Scheithauer, BW
    CalleRodrigue, R
    Abboud, C
    Davis, DH
    Kovacs, K
    Lloyd, RV
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (03) : 963 - 968
  • [72] Tamoxifen, raloxifene, and the prevention of breast cancer
    Jordan, VC
    Morrow, M
    [J]. ENDOCRINE REVIEWS, 1999, 20 (03) : 253 - 278
  • [73] Kabuto M, 2000, CANCER EPIDEM BIOMAR, V9, P575
  • [74] The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor
    Kaulsay, KK
    Zhu, T
    Bennett, WF
    Lee, KO
    Lobie, PE
    [J]. ENDOCRINOLOGY, 2001, 142 (02) : 767 - 777
  • [75] The tertiary structure and backbone dynamics of human prolactin
    Keeler, C
    Dannies, PS
    Hodsdon, ME
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2003, 328 (05) : 1105 - 1121
  • [76] Kelly P A, 1991, Oxf Surv Eukaryot Genes, V7, P29
  • [77] Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin
    Kindblom, J
    Dillner, K
    Sahlin, L
    Robertson, F
    Ormandy, C
    Törnell, J
    Wennbo, H
    [J]. ENDOCRINOLOGY, 2003, 144 (06) : 2269 - 2278
  • [78] Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels
    Kindblom, J
    Dillner, K
    Ling, C
    Törnell, J
    Wennbo, H
    [J]. PROSTATE, 2002, 53 (01) : 24 - 33
  • [79] Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites
    Kinet, S
    Bernichtein, S
    Kelly, PA
    Martial, JA
    Goffin, V
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (37) : 26033 - 26043
  • [80] Identification and characterization of the prolactin-binding protein in human serum and milk
    Kline, JB
    Clevenger, CV
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) : 24760 - 24766